IMerge Clinical Data in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents



Guillermo Garcia-Manero, MD
Professor, Department of Leukemia, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, explores imetelstat trial results of patients with transfusion-dependent lower-risk myelodysplastic syndromes who experience failure to or are ineligible for treatment with erythropoiesis-stimulating agents.

Related Items

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: